ClinicalTrials.gg
RecruitingNCT06649110Updated Jul 21, 2026

A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)

A Phase 1/2 interventional study of LTP and Placebo in Healthy Volunteers, Pulmonary Arterial Hypertension, sponsored by Novartis Pharmaceuticals. Recruiting at 87 sites in 18 countries. Open to participants aged 18 Years to 100 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-21.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
232
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies in Pulmonary Arterial Hypertension by Novartis — 1 open to participants now, 1 under way, none of them phase 3. Pulmonary Arterial Hypertension · Novartis.

Planned enrollment
Largest of 12
232 · median 27
Started
2024
the only one that year
Phase 1/2
Only one
of the 12
Registered
12th of 12
by date

Among the 12 studies in Pulmonary Arterial Hypertension by Novartis, this one has the largest planned enrollment, is the only one that started in 2024, is the only one in phase 1/2, and was the 12th registered.

Pulmonary Arterial Hypertension

699 studies on the registry are indexed under Pulmonary Arterial Hypertension; 140 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

1 of the 12 studies in Pulmonary Arterial Hypertension by Novartis is open now, in 12 countries.

By country, each count listing its studies:

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Pulmonary Arterial Hypertension by Novartis, or all of them as a file.
02

Study summary

A study to learn about the treatment LTP001 in healthy participants (Part A) and in participants with PAH (Part B)

Read the detailed description

The CLTP001A12202 study will explore the safety, tolerability, and pharmacokinetics of LTP001 in healthy volunteers (Part A) and will evaluate the safety and efficacy (Part B) followed by safety extension in participants with pulmonary arterial hypertension.

03

Conditions studied

  • Healthy Volunteers, Pulmonary Arterial Hypertension

Keywords

  • LTP001
  • pulmonary arterial hypertension
  • PAH
  • PVR
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Part A Inclusion Criteria:

  • Healthy males and non- females

Part A Exclusion Criteria:

  • or cardiac abnormalities, any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of drugs, or which may jeopardize the participant in the study Other protocol-defined inclusion/exclusion criteria may apply.
  • For Japanese cohorts: participants per protocol should be first generation Japanese or up to third generation Japanese as defined in inclusion criteria 7 of the protocol.

Part B Inclusion Criteria:

-Confirmed diagnosis of PAH, pre-randomization PVR ≥400 dyn.sec.cm-5, treatment with stable doses of standard-of-care PAH therapies, 6-minute walk distance ≥ 150 m and ≤450 m.

Part B Exclusion Criteria:

Any surgical or medical condition which may place the participant at higher risk from his/her participation in the study Women of child-bearing potential unless they are using highly effective methods of Sexually active males unwilling to use a condom during intercourse while taking study treatment and for 24 hours after stopping study treatment.

History of to any of the study treatments or

Other protocol-defined inclusion / exclusion criteria may apply

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
232 participants (estimated)

Study arms

  • Experimental
    LTP001 Dose 1

    Drug: LTP

  • Experimental
    LTP001 Dose 2

    Drug: LTP

  • Experimental
    LTP001 Dose 3

    Drug: LTP

  • Placebo comparator
    Placebo

    matching placebo

    Drug: Placebo

Interventions

  • DrugLTP

    LTP001

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Part A- Number of participants with Adverse events (AEs) and Serious Adverse events (SAEs)

    Safety endpoints, including vital signs, ECG, clinical laboratory evaluations and adverse events up to and including the end-of-study visit.

    Time frame: Baseline to Day 35

  2. Part B-Treatment Period 1: Change in pulmonary vascular resistance (PVR)

    PVR is a hemodynamic variable of pulmonary circulation and is measured by right heart catheterization.

    Time frame: Baseline to Week 24

  3. Part B-Treatment Period 2: Number of participants with Adverse events (AEs) and Serious Adverse events (SAEs)

    Safety endpoints, including vital signs, ECG, clinical laboratory evaluations, treatment-emergent adverse events and discontinuations due to adverse events.

    Time frame: From Day 1 until Week 106

Secondary outcomes

  1. Part A- Maximum observed plasma concentrations (Cmax)

    Cmax is defined as the maximum (peak) observed concentration following a dose.

    Time frame: Baseline to Day 35

  2. Part A- Time to reach maximum plasma concentration (Tmax)

    Tmax is defined as the time to reach maximum (peak) concentration following a dose.

    Time frame: Baseline to Day 35

  3. Part A- Area under plasma concentration-time curve from time zero to the last measurable concentration sampling time (AUClast)

    AUClast is the area under the plasma concentration-time curve from time zero to the time of last quantifiable concentration (tlast).

    Time frame: Baseline to Day 35

  4. Part A- Area under the plasma concentration-time curve from time zero extrapolated to infinity (AUC[0-inf])

    The AUC is the area under the plasma concentration from time zero to infinity (mass x time x volume-1).

    Time frame: Baseline to Day 35

  5. Part A- Terminal elimination half-life (T1/2)

    T1/2 is the elimination half-life associated with the terminal slope.

    Time frame: Baseline to Day 35

  6. Part B-Treatment Period 1: Change in the Six-minute Walk Test (6MWT)

    The 6MWD test is self-paced, with standardized instructions and encouragement being given as participants walk as far as possible over 6 minutes through a flat corridor.

    Time frame: Baseline to Week 24

  7. Part B-Treatment Period 1: Change in N-terminal pro-brain natriuretic peptide (NT-proBNP)

    N-terminal pro brain natriuretic peptide (NTproBNP) are peptide (small proteins) that are either hormones or part of the peptide that contained the hormone at one time. They are continually produced in small quantities in the heart and released in larger quantities when the heart senses that it needs to work harder, as in heart failure.

    Time frame: Baseline to Week 24

  8. Part B-Treatment Period 1: Change in World Health Organization (WHO) functional class (FC)

    The Investigator or study staff will assign a WHO functional class to a participant based on reports of symptoms and activity limitation. * Class I: symptom-free when physically active or resting. * Class II: no symptoms at rest, but normal activities such as climbing the stairs, grocery shopping, or making the bed cause some discomfort and shortness of breath. * Class III: resting may be symptom-free, but normal chores around the house are greatly limited due to shortness of breath and feeling tired. * Class IV: symptoms at rest and severe symptoms with an activity

    Time frame: Baseline to Week 24

  9. Part B-Treatment Period 2: Change in the Six-minute Walk Test (6MWT)

    The 6MWD test is self-paced, with standardized instructions and encouragement being given as participants walk as far as possible over 6 minutes through a flat corridor.

    Time frame: Baseline to Month 18

  10. Part B-Treatment Period 2: Change in World Health Organization (WHO) functional class (FC)

    The Investigator or study staff will assign a WHO functional class to a participant based on reports of symptoms and activity limitation. * Class I: symptom-free when physically active or resting. * Class II: no symptoms at rest, but normal activities such as climbing the stairs, grocery shopping, or making the bed cause some discomfort and shortness of breath. * Class III: resting may be symptom-free, but normal chores around the house are greatly limited due to shortness of breath and feeling tired. * Class IV: symptoms at rest and severe symptoms with an activity

    Time frame: Baseline to Month 18

07

Study locations

87 of 87 sites recruiting
  • Arizona Pulmonary Specialists Ltd
    Scottsdale, Arizona 85258, United States
    Recruiting
    • · Contact+1 602 271 0832
    • Akshay Muralidhar · Principal investigator
  • UC Irvine Medical Center
    Orange, California 92868-3298, United States
    Recruiting
    • · Contact+1 714 456 6037
    • Bassam Yaghmour · Principal investigator
  • Stanford Medical Center
    Stanford, California 94305, United States
    Recruiting
    • · Contact+1 650 725 5495
    • Roham Zamanian · Principal investigator
  • Univ Colorado Hospital
    Aurora, Colorado 80045, United States
    Recruiting
    • · Contact+1 720 848 6567
    • David B Badesch · Principal investigator
  • Central Florida Pulmonary Group
    Orlando, Florida 32803-5734, United States
    Recruiting
    • · Contact+1 407 841 1100
    • Syed Mobin · Principal investigator
  • University of South Florida
    Tampa, Florida 33606-3475, United States
    Recruiting
    • · Contact+1 813 844 7137
    • Ricardo Restrepo-Jaramillo · Principal investigator
  • Emory University School of Medicine
    Atlanta, Georgia 30322, United States
    Recruiting
    • · Contact+1 404 778 3261
    • Micah Fisher · Principal investigator
  • U of Kansas Medical Center
    Kansas City, Kansas 66160, United States
    Recruiting
    • · Contact+1 913 588 9722
    • Leslie Spikes · Principal investigator
  • Norton Infectious Diseases Specialists
    Louisville, Kentucky 40202, United States
    Recruiting
    • · Contact+1 502 587 8000
    • John Wesley McConnell · Principal investigator
  • Tufts Medical Center
    Boston, Massachusetts 02111, United States
    Recruiting
    • · Contact+1 617 636 4288
    • Nicholas Hill · Principal investigator
  • Lahey Hospital and Medical Center
    Burlington, Massachusetts 01805, United States
    Recruiting
    • · Contact+1 781 744 3874
    • Ioana Preston · Principal investigator
  • Sky Integrative Medical Center SKYCRNG PPDS
    Ridgeland, Mississippi 39157-5179, United States
    Recruiting
    • Bob Hutchins · Principal investigator
  • Summit Health Eastside Clinic
    Bend, Oregon 97701, United States
    Recruiting
    • Jeremy Feldman · Principal investigator
  • Allegheny General Hospital
    Pittsburgh, Pennsylvania 15212-4756, United States
    Recruiting
    • Hayah Kassis-George · Principal investigator
  • Statcare Pulmonary Consultants
    Knoxville, Tennessee 37919, United States
    Recruiting
    • · Contact+1 941 924 9800
    • John Swisher · Principal investigator
  • PPD Development LP
    Austin, Texas 78744, United States
    Recruiting
    • · Contact+1 512 447 2985
    • Jia Chang · Principal investigator
  • PPD Development LP
    Austin, Texas 78744, United States
    Recruiting
    • Shawn Searle · Principal investigator
  • UT Southwestern Medical Center
    Dallas, Texas 75390, United States
    Recruiting
    • · Contact+1 214 645 6488
    • Kelly Chin · Principal investigator
  • The University of Utah
    Salt Lake City, Utah 84132-0001, United States
    Recruiting
    • · Contact+1 801 213 4086
    • Katharine Clapham · Principal investigator
  • Pul Ass Richmond Inc P A R
    Richmond, Virginia 23230-1709, United States
    Recruiting
    • · Contact+1 804 288 5945
    • Shilpa Johri · Principal investigator
  • Novartis Investigative Site
    Buenos Aires, Buenos Aires F.D. 1199, Argentina
    Recruiting
  • Novartis Investigative Site
    CABA, C1426ABP, Argentina
    Recruiting
  • Novartis Investigative Site
    Río Cuarto, X5800AEV, Argentina
    Recruiting
  • Novartis Investigative Site
    San Miguel de Tucumán, T4000AXL, Argentina
    Recruiting
  • Novartis Investigative Site
    Santa Fe, S3000EOZ, Argentina
    Recruiting
  • Novartis Investigative Site
    Camperdown, New South Wales 2050, Australia
    Recruiting
  • Novartis Investigative Site
    Darlinghurst, New South Wales 2010, Australia
    Recruiting
  • Novartis Investigative Site
    New Lambton Heights, New South Wales 2305, Australia
    Recruiting
  • Novartis Investigative Site
    Adelaide, South Australia 5000, Australia
    Recruiting
  • Novartis Investigative Site
    Leuven, Vlaams Brabant 3000, Belgium
    Recruiting
  • Novartis Investigative Site
    Porto Alegre, Rio Grande do Sul 90035-074, Brazil
    Recruiting
  • Novartis Investigative Site
    Prague, 128 08, Czechia
    Recruiting
  • Novartis Investigative Site
    Prague, 14021, Czechia
    Recruiting
  • Novartis Investigative Site
    Angers, France 49933, France
    Recruiting
  • Novartis Investigative Site
    Brest, 29200, France
    Recruiting
  • Novartis Investigative Site
    Clamart, 92141, France
    Recruiting
  • Novartis Investigative Site
    Grenoble, 38043, France
    Recruiting
  • Novartis Investigative Site
    Montpellier, 34295, France
    Recruiting
  • Novartis Investigative Site
    Nice, 06001, France
    Recruiting
  • Novartis Investigative Site
    Pessac, 33604, France
    Recruiting
  • Novartis Investigative Site
    Poitiers, 86021, France
    Recruiting
  • Novartis Investigative Site
    Saint-Priest-en-Jarez, 42270, France
    Recruiting
  • Novartis Investigative Site
    Strasbourg, 67091, France
    Recruiting
  • Novartis Investigative Site
    Toulouse, 31059, France
    Recruiting
  • Novartis Investigative Site
    Vandœuvre-lès-Nancy, 54511, France
    Recruiting
  • Novartis Investigative Site
    Regensburg, Bavaria 93053, Germany
    Recruiting
  • Novartis Investigative Site
    Dresden, Saxony 01307, Germany
    Recruiting
  • Novartis Investigative Site
    Berlin, 13125, Germany
    Recruiting
  • Novartis Investigative Site
    Berlin, 14050, Germany
    Recruiting
  • Novartis Investigative Site
    Giessen, 35392, Germany
    Recruiting
  • Novartis Investigative Site
    Greifswald, 17475, Germany
    Recruiting
  • Novartis Investigative Site
    Heidelberg, 69120, Germany
    Recruiting
  • Novartis Investigative Site
    Homburg, 66421, Germany
    Recruiting
  • Novartis Investigative Site
    Athens, 106 76, Greece
    Recruiting
  • Novartis Investigative Site
    Chaïdári, 124 62, Greece
    Recruiting
  • Novartis Investigative Site
    Thessaloniki, 54636, Greece
    Recruiting
  • Novartis Investigative Site
    Foggia, FG 71122, Italy
    Recruiting
  • Novartis Investigative Site
    Monza, MB 20900, Italy
    Recruiting
  • Novartis Investigative Site
    Palermo, PA 90127, Italy
    Recruiting
  • Novartis Investigative Site
    Pavia, PV 27100, Italy
    Recruiting
  • Novartis Investigative Site
    Roma, RM 00161, Italy
    Recruiting
  • Novartis Investigative Site
    Sassari, SS 07100, Italy
    Recruiting
  • Novartis Investigative Site
    Ivrea, TO 10015, Italy
    Recruiting
  • Novartis Investigative Site
    Trieste, TS 34149, Italy
    Recruiting
  • Novartis Investigative Site
    Riga, LV 1002, Latvia
    Recruiting
  • Novartis Investigative Site
    Monterrey, Nuevo León 64460, Mexico
    Recruiting
  • Novartis Investigative Site
    Monterrey, Nuevo León 64718, Mexico
    Recruiting
  • Novartis Investigative Site
    San Luis Potosí City, San Luis Potosí 78200, Mexico
    Recruiting
  • Novartis Investigative Site
    Poznan, 61 545, Poland
    Recruiting
  • Novartis Investigative Site
    Almada, 2805-267, Portugal
    Recruiting
  • Novartis Investigative Site
    Lisbon, 1769 001, Portugal
    Recruiting
  • Novartis Investigative Site
    Timișoara, Timiș County 300310, Romania
    Recruiting
  • Novartis Investigative Site
    Bucharest, 050159, Romania
    Recruiting
  • Novartis Investigative Site
    Belgrade, Serbia 11000, Serbia
    Recruiting
  • Novartis Investigative Site
    Kamenitz, 21204, Serbia
    Recruiting
  • Novartis Investigative Site
    Niš, 18108, Serbia
    Recruiting
  • Novartis Investigative Site
    Santiago Compostela, A Coruna 15706, Spain
    Recruiting
  • Novartis Investigative Site
    Marbella, Andalusia 29600, Spain
    Recruiting
  • Novartis Investigative Site
    Toledo, Castille-La Mancha 45071, Spain
    Recruiting
  • Novartis Investigative Site
    Barcelona, Catalonia 08003, Spain
    Recruiting
  • Novartis Investigative Site
    Las Palmas de Gran C, Las Palmas 35016, Spain
    Recruiting
  • Novartis Investigative Site
    Barcelona, 08035, Spain
    Recruiting
  • Novartis Investigative Site
    Seville, 41013, Spain
    Recruiting
  • Novartis Investigative Site
    Sheffield, South Yorkshire S10 2JF, United Kingdom
    Recruiting
  • Novartis Investigative Site
    Cambridge, CB2 0AY, United Kingdom
    Recruiting
  • Novartis Investigative Site
    London, EC1A 7BE, United Kingdom
    Recruiting
  • Novartis Investigative Site
    London, SW3 6PH, United Kingdom
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.

Data sharing details ↗ · www.clinicalstudydatarequest.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2024 (actual). Primary completion is estimated for Nov 2028, 49 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 17, 2024
First posted
Oct 18, 2024
StartActual
Oct 24, 2024
Primary completionEst.
Nov 29, 2028
CompletionEst.
Dec 31, 2028
Last update
Jul 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06649110
Responsible party
Sponsor
First posted
Oct 18, 2024
Start date
Oct 24, 2024
Primary completion
Nov 29, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Jul 21, 2026

Study contacts

Novartis Pharmaceuticals
Contact
novartis.email@novartis.com
1-888-669-6682
Novartis Pharmaceuticals
Contact
+41613241111
Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion